Vbl_Logo.png
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer
September 17, 2021 07:00 ET | VBL Therapeutics
The OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date;Remains on track to complete enrollment in 1Q22 TEL...
Vbl_Logo.png
VBL Therapeutics to Present at Upcoming Conferences
September 10, 2021 07:00 ET | VBL Therapeutics
TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd...
Vbl_Logo.png
VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility
August 30, 2021 07:00 ET | VBL Therapeutics
U.S. FDA CMC clearance of VB-111 produced in Modiin, Israel facility an important milestone toward potential commercializationOVAL Phase 3 trial evaluating VB-111 in platinum resistant ovarian cancer...
CB2 Insights.jpg
CB2 Insights to Host Q1 2020 Earnings Call on July 15, 2020
July 08, 2020 16:45 ET | CB2 Insights
TORONTO, July 08, 2020 (GLOBE NEWSWIRE) -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF), will be hosting its Q1 2020 earnings call on Wednesday, July 15, 2020 at 9:00 a.m....
Altasciences_Gradient_V_RGB.png
Dr. Joseph A. Francisco Appointed Chief Toxicologist at Altasciences
June 22, 2020 09:19 ET | Altasciences Company Inc.
LAVAL, Quebec, June 22, 2020 (GLOBE NEWSWIRE) -- Altasciences announced today the appointment of Dr. Joseph A. Francisco as Chief Toxicologist, effective June 22, 2020. Dr. Francisco is a...
CB2 Insights.jpg
VIVO and CB2 Insights Enter Technology and Research Partnership
October 29, 2019 07:48 ET | CB2 Insights
Partnership to focus on implementing a medical product development strategy for VIVO’s global medical cannabis offering, utilizing CB2 Insights’ leading technology platform Sail and research...
Aldevron Names Diane Rogers as Senior Vice President Commercial Development
October 09, 2019 15:46 ET | Aldevron
Fargo, North Dakota, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Diane Rogers has joined Aldevron as its Senior Vice President Commercial Development. In her role, Rogers will be responsible for leading the...
Abeona Therapeutics.jpg
Abeona Therapeutics to Host R&D Day on December 6, 2018
November 29, 2018 08:45 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics.jpg
Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer
July 26, 2018 08:30 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 26, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics.jpg
Abeona Therapeutics Provides Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT Meeting
May 18, 2018 09:25 ET | Abeona Therapeutics Inc.
ABO-102 18-month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver...